Comparison of treatment outcomes between slow coagulation transscleral cyclophotocoagulation and micropulse transscleral laser treatment
- PMID: 39397105
- PMCID: PMC11471840
- DOI: 10.1038/s41598-024-75246-y
Comparison of treatment outcomes between slow coagulation transscleral cyclophotocoagulation and micropulse transscleral laser treatment
Abstract
This study compared treatment outcomes of slow coagulation transscleral cyclophotocoagulation (SC-CPC, 65 eyes) and micropulse transscleral laser treatment (MPL, 134 eyes) in patients with medically uncontrolled glaucoma. Success was defined as achieving an intraocular pressure (IOP) of 6-21 mmHg with a ≥ 20% reduction from baseline, no reoperation for glaucoma, and no loss of light-perception vision. Visual acuity, number of glaucoma medication, corneal endothelial cell count, aqueous flare values, and complications were analyzed. At 12 months, mean IOP decreased from 32.2 ± 13.4 to 17.9 ± 8.3 mmHg in the SC-CPC group and from 26.4 ± 10.8 to 16.5 ± 6.8 mmHg in the MPL group. No significant changes were observed in visual acuity, medication count, or corneal endothelial cell count. Aqueous flare values increased immediately after the procedure and gradually decreased in both groups, with greater changes at 1 week significantly associated with greater IOP reduction (p < 0.05). Pupillary abnormalities were found in 5 eyes (4.5%) of the MPL group, with no severe complications. The 12-month success rates were 50.1% for SC-CPC and 38.2% for MPL (p = 0.131). Both SC-CPC and MPL effectively controlled IOP, with early postoperative aqueous flare values predicting treatment outcomes.
Keywords: Cyclophotocoagulation; Glaucoma; Micropulse laser; Surgery.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
The authors declare no competing interests.
Figures



Similar articles
-
Comparison of safety and effectiveness of micropulse transscleral cyclophotocoagulation and "slow cook" diode laser transscleral cyclophotocoagulation in patients with refractory open-angle glaucoma.Arq Bras Oftalmol. 2024 Aug 2;88(1):e20230103. doi: 10.5935/0004-2749.2023-0103. eCollection 2024. Arq Bras Oftalmol. 2024. PMID: 39109740
-
Micropulse transscleral cyclophotocoagulation using a standard protocol in patients with refractory glaucoma naive of cyclodestruction.Eur J Ophthalmol. 2021 Jan;31(1):112-119. doi: 10.1177/1120672119877586. Epub 2019 Sep 23. Eur J Ophthalmol. 2021. PMID: 31544505
-
Transscleral cyclophotocoagulation with MicroPulse® laser versus Ahmed valve implantation in patients with advanced primary open-angle glaucoma.Int Ophthalmol. 2021 Apr;41(4):1271-1282. doi: 10.1007/s10792-020-01682-0. Epub 2021 Jan 3. Int Ophthalmol. 2021. PMID: 33392944 Clinical Trial.
-
Cyclodestructive procedures for refractory glaucoma.Cochrane Database Syst Rev. 2019 Mar 10;3(3):CD012223. doi: 10.1002/14651858.CD012223.pub2. Cochrane Database Syst Rev. 2019. PMID: 30852841 Free PMC article.
-
Comparison of Aqueous Flare Values after Micropulse Transscleral Laser Treatment and Continuous Wave Transscleral Cyclophotocoagulation.Ocul Immunol Inflamm. 2023 Apr;31(3):541-549. doi: 10.1080/09273948.2022.2042315. Epub 2022 May 6. Ocul Immunol Inflamm. 2023. PMID: 35522198 Review.
References
-
- Pastor, S. A. et al. Cyclophotocoagulation: a report by the American Academy of Ophthalmology. Ophthalmology. 108, 2130–2138. 10.1016/s0161-6420(01)00889-2 (2001). - PubMed
-
- Anand, N., Klug, E. & Nirappel, A. Solá-Del Valle, D. A review of Cyclodestructive procedures for the Treatment of Glaucoma. Semin Ophthalmol.35, 261–275. 10.1080/08820538.2020.1810711 (2020). - PubMed
-
- Fong, Y. Y. Y., Wong, B. K. T., Li, F. C. H. & Young, A. L. A retrospective study of Transcleral Cyclophotocoagulation using the slow coagulation technique for the treatment of refractory Glaucoma. Semin Ophthalmol.34, 398–402. 10.1080/08820538.2019.1638946 (2019). - PubMed
-
- Khodeiry, M. M., Lauter, A. J., Sayed, M. S., Han, Y. & Lee, R. K. Primary slow-coagulation transscleral cyclophotocoagulation laser treatment for medically recalcitrant neovascular glaucoma. Br. J. Ophthalmol.10.1136/bjophthalmol-2021-319757 (2021). - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical